Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.


Gruenwald V., Karakiewicz P. I. , Bavbek S. E. , Miller K., Machiels J. H. , Lee S., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.29, 2011 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 29 Konu: 15
  • Basım Tarihi: 2011
  • Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY